This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Subscribe To Our Newsletter & Stay Updated
